GRK2 and Hypertension: For instance, a recent publication suggests that a global GRK2 downregulation by using a silencing construct under the control of the U6 mouse polymerase III promoter may have detrimental outcomes in kidney function and development (Tutunea-Fatan et al., 2018), thus suggesting that therapeutic strategies that target GRK2 activity, not expression, could be safer in particular for the treatment of hypertension (Tutunea-Fatan et al., 2015).